WO2004024205A1 - Verfahren zur herstellung eines antimikrobiellen kunststoffproduktes - Google Patents
Verfahren zur herstellung eines antimikrobiellen kunststoffproduktes Download PDFInfo
- Publication number
- WO2004024205A1 WO2004024205A1 PCT/EP2003/010049 EP0310049W WO2004024205A1 WO 2004024205 A1 WO2004024205 A1 WO 2004024205A1 EP 0310049 W EP0310049 W EP 0310049W WO 2004024205 A1 WO2004024205 A1 WO 2004024205A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- silver
- salts
- sulfate
- plastic
- antimicrobial
- Prior art date
Links
- 229920003023 plastic Polymers 0.000 title claims abstract description 51
- 239000004033 plastic Substances 0.000 title claims abstract description 51
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 32
- 239000004599 antimicrobial Substances 0.000 title claims abstract description 13
- 229910052751 metal Inorganic materials 0.000 claims abstract description 37
- 239000002184 metal Substances 0.000 claims abstract description 37
- 239000000047 product Substances 0.000 claims description 46
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 44
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 42
- 239000000084 colloidal system Substances 0.000 claims description 22
- 229910052709 silver Inorganic materials 0.000 claims description 21
- 239000004332 silver Substances 0.000 claims description 20
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 claims description 19
- 229910000367 silver sulfate Inorganic materials 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 14
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 claims description 11
- 229940019931 silver phosphate Drugs 0.000 claims description 11
- 229910000161 silver phosphate Inorganic materials 0.000 claims description 11
- 229920002635 polyurethane Polymers 0.000 claims description 10
- 239000004814 polyurethane Substances 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000010954 inorganic particle Substances 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- 238000001125 extrusion Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- UBXAKNTVXQMEAG-UHFFFAOYSA-L strontium sulfate Chemical compound [Sr+2].[O-]S([O-])(=O)=O UBXAKNTVXQMEAG-UHFFFAOYSA-L 0.000 claims description 4
- 229910021485 fumed silica Inorganic materials 0.000 claims description 3
- 238000001746 injection moulding Methods 0.000 claims description 3
- 239000013067 intermediate product Substances 0.000 claims description 3
- 239000011146 organic particle Substances 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 239000004408 titanium dioxide Substances 0.000 claims description 3
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- 150000000703 Cerium Chemical class 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- 150000001621 bismuth Chemical class 0.000 claims description 2
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 claims description 2
- 150000001879 copper Chemical class 0.000 claims description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 2
- 238000004898 kneading Methods 0.000 claims description 2
- 239000010445 mica Substances 0.000 claims description 2
- 229910052618 mica group Inorganic materials 0.000 claims description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 2
- 150000003057 platinum Chemical class 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 239000010457 zeolite Substances 0.000 claims description 2
- 150000003751 zinc Chemical class 0.000 claims description 2
- 150000003754 zirconium Chemical class 0.000 claims description 2
- 150000003378 silver Chemical class 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
- 229960001031 glucose Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- -1 polyethylene Polymers 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 7
- 241000191963 Staphylococcus epidermidis Species 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- 239000012876 carrier material Substances 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 101710134784 Agnoprotein Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000002639 bone cement Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000005470 impregnation Methods 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001631457 Cannula Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 229910052726 zirconium Inorganic materials 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- DSUFPYCILZXJFF-UHFFFAOYSA-N 4-[[4-[[4-(pentoxycarbonylamino)cyclohexyl]methyl]cyclohexyl]carbamoyloxy]butyl n-[4-[[4-(butoxycarbonylamino)cyclohexyl]methyl]cyclohexyl]carbamate Chemical compound C1CC(NC(=O)OCCCCC)CCC1CC1CCC(NC(=O)OCCCCOC(=O)NC2CCC(CC3CCC(CC3)NC(=O)OCCCC)CC2)CC1 DSUFPYCILZXJFF-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- IYNWNKYVHCVUCJ-UHFFFAOYSA-N bismuth Chemical compound [Bi].[Bi] IYNWNKYVHCVUCJ-UHFFFAOYSA-N 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910021432 inorganic complex Inorganic materials 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000012273 nephrostomy Methods 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229920005606 polypropylene copolymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- HAAYBYDROVFKPU-UHFFFAOYSA-N silver;azane;nitrate Chemical compound N.N.[Ag+].[O-][N+]([O-])=O HAAYBYDROVFKPU-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- SDKPSXWGRWWLKR-UHFFFAOYSA-M sodium;9,10-dioxoanthracene-1-sulfonate Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)[O-] SDKPSXWGRWWLKR-UHFFFAOYSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052845 zircon Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
Definitions
- the invention relates to processes for producing metal-containing antimicrobial plastic products and to products obtainable by the process, in particular products for medical needs.
- Plastic objects are used very frequently in the medical field and for a wide variety of purposes.
- the problem with the use of plastic products for medical purposes is that the plastics can be easily colonized with germs. The germs settle on the plastic surface and form a "biofilm".
- the consequence of the use of micro-org a n i s me n b e s i ed plastic objects are often infections.
- It is known that the use of plastic catheters and cannulas can easily lead to infection by bacterial immigration. Such infections are particularly serious and common. in central venous short, medium and long-term catheters as well as in the urological area, where urethral and ureteral catheters are routinely used, and in diverting valve systems. In the Federal Republic of Germany alone, around 12 to 15 patients die every day as a result of infections that can be attributed to the use of microbially contaminated catheters.
- WO87 / 03495 and WO89 / 04682 describe the impregnation of medical devices or implants with antibiotics.
- the problem with impregnation with antibiotics is the formation and selection of resistant microorganisms.
- Another approach to reducing infections when using plastic products is the use of metals or metal alloys, for example in the case of catheters (DE 40 41 721, DE 27 20 776 and DE 33 02 567).
- the antimicrobial property of silver is of particular importance. Traces of silver and its salts already show a bacteriostatic and bactericidal effect.
- US 4,054,139 discloses a catheter in which a silver-containing, oligodynamic material has been applied to inner and outer surfaces for prophylaxis against infection.
- the approaches described have so far not been able to achieve satisfactory results with regard to sterility with the impregnation of plastic products in every respect, in particular at the start of use.
- the object of the present invention is therefore to provide a method for producing plastic products which have a satisfactory antimicrobial activity.
- the combination of an antimicrobial metal colloid and a soluble, preferably sparingly soluble, salt of an antimicrobial metal gives a satisfactory antimicrobial activity.
- the plastic products according to the invention also achieve a significantly improved immediate effect against microorganisms.
- the antimicrobial activity is significantly improved at the beginning compared to a plastic product of the prior art, as described, for example, in WO 01/09229.
- a significantly higher antimicrobial effectiveness of the plastic products according to the invention can be shown (cf. Table 1).
- the plastic products according to the present invention also have no increased cytotoxicity compared to products of the prior art, a further advantage is that no thrombogenicity is observed when using the plastic products according to the invention.
- Antimicrobial plastic products in the sense of the invention are products which have activity against microorganisms, in particular against bacteria and / or fungi. This can be both a bacteriostatic action and a bactericidal action.
- any antimicrobial plastic product can be produced by the method according to the invention; products are preferably produced which are used in the medical field. It may, for example, catheters, tubing, tubes, especially endotracheal tubes. Objects used in urology, bone cement, preferably bone cement consisting of methyl acrylate, Goretex tissue, toothbrushes, silicone plastics, plastic foils, textiles, for example for the manufacture of work clothing, diapers and / or parts thereof. In a particularly preferred embodiment of the method according to the invention, catheters are produced.
- any polymeric compounds which are usually used in the medical field can be used as starting materials for the production of the antimicrobial plastic products according to the invention.
- Preferred polymers are e.g. Polyurethanes, polyethylene, polypropylene, cross-linked polysiloxanes, (meth) acrylate-based polymers, cellulose and cellulose derivatives, polycarbonates, ABS, tetrafluoroethylene polymers, polyethylene terephthalates and the corresponding copolymers.
- Polyurethane, polyethylene and polypropylene and polyethylene / polypropylene copolymers are particularly preferably used, most preferred being polyurethane.
- the preliminary product can comprise further additives.
- Additives can be, for example, inorganic or organic substances.
- the precursor can include all inorganic and organic substances that are inert and medicinal are harmless, such as barium sulfate, calcium sulfate, strontium sulfate, titanium dioxide, aluminum oxide, silicon dioxide, zeolites, calcium fluoride (CaF 2 ), mica, talc, pyrogenic silica, calcium hydroxylapatite, kaolin, zirconium and / or microcellulose.
- Preferred inorganic substances are barium sulfate, which can also be used as an X-ray contrast medium for special application forms, and zircon.
- one or more constituents of the preliminary product are treated with a metal colloid.
- One or more polymeric materials and / or one or more inorganic or organic particles can be treated with the metal colloid.
- the carrier materials for the metal colloid can be present in the preliminary product in an amount of about 5 to 50% by weight.
- barium sulfate is used as the carrier material, it is usually present in an amount of about 5 to 30% by weight, particularly preferably in an amount of about 20% by weight.
- silicon dioxide is used as the carrier material, it is present in an amount of approximately 30 to 50% by weight, preferably approximately 40% by weight.
- the metal colloid with which one or more constituents of the preliminary product are treated is suitably produced by reducing metal salt solutions.
- reducing metal salt solutions When using silver, this is mixed with a reducing agent, for example as an ammoniacal silver nitrate solution.
- a reducing agent for example as an ammoniacal silver nitrate solution.
- protective substances such as gelatin, silica, starch, dextrin, gum arabic, polyvinyl alcohol or complexing agents such as ethylenediaminetetraacetic acid can optionally be used. It is preferable to work without protective substances.
- Suitable reducing agents are, for example, aldehydes (for example acetaldehyde), aldoses (for example glucose), quinones (for example hydroquinone), inorganic complex hydrides (sodium or potassium borate), reducers Nitrogen compounds (e.g. hydrazine, polyethyleneimine), ascorbic acid, tartaric acid and citric acid.
- aldehydes for example acetaldehyde
- aldoses for example glucose
- quinones for example hydroquinone
- inorganic complex hydrides sodium or potassium borate
- Nitrogen compounds e.g. hydrazine, polyethyleneimine
- ascorbic acid tartaric acid and citric acid.
- the color of the coated carrier material can also be controlled by varying the reducing agents and varying or omitting the stabilizers.
- antimicrobial metals such as, for example, silver, copper, gold, zinc, zirconium, bismuth (bismuth) or cerium, and mixtures thereof, are suitable for the process according to the invention.
- Silver which has a high antimicrobial activity, is particularly preferred.
- copper is preferably used, which advantageously also has an activity against fungi.
- the amount of the metal colloid is advantageously about 0.1 to 10, preferably about 0.5 to 5% by weight.
- the application of the metal colloid to one or more components of the preliminary product can either be carried out in one step or can be followed by drying and repeated several times.
- a very high metal concentration can be achieved with both methods.
- the particle size of the metal can be controlled by varying the reducing agents and varying or omitting the stabilizers. If silver is used as the metal colloid, the preferred particle size is in the range from 10 to 50 nm. Silver of this particle size is referred to as nanosilver.
- silver remaining in the solution is precipitated by adding phosphoric acid as silver phosphate, which is referred to below as "silver phosphate in statu nascendi" and is characterized by particularly rapid onset of the antimicrobial effect.
- the amount of the metal colloid is chosen so that a sufficient part of the surface of the plastic product consists of metal particles in order to achieve an antimicrobial effectiveness.
- a soluble or sparingly soluble salt of an antimicrobial metal is further added to the preliminary product.
- This is preferably a silver salt, zinc salt, copper salt, cerium salt, platinum salt, zirconium salt, bismuth salt and / or gold salt and mixtures thereof.
- all soluble or sparingly soluble salts of antimicrobially active metals are suitable which are resistant to the action of light and are physiologically harmless.
- the amount of the metal salt used can be from 0.1 to 5% by weight, based on the total weight of the preliminary product, preferably from 0.5 to 1% by weight.
- the mixture obtained is processed further in order to obtain a plastic product.
- This can be done, for example, by extrusion, injection molding, mixing, kneading or (hot) pressing.
- Preferred molding processes are extrusion and injection molding.
- plastic products which can be obtained by the process according to the invention. It is preferably plastic products that are used in the medical field.
- the method according to the invention produces catheters.
- the preferred medical products are venous catheters for short-term implantation, in which both the outside of the catheter and each lumen inside, the Luer lock and the distributor consist of the material obtained according to the invention. Experiments have shown that an inoculum size of 10 9 germs with which the surface has been contaminated is completely eliminated in less than 9 hours.
- peripheral venous cannulas peripheral venous cannulas, Sheldon catheters for implantation over 6 weeks for hemodialysis, Hickman-type catheters for long-term implantation with a cuff made of material according to the invention (antimicrobial activity determined for at least 1 year), port catheters, with at least the port chamber made of material produced according to the invention consists, expediently, also of all other components of the same, ventricular drainage catheter (minimum duration of effectiveness 3 years), bladder catheter, cystostomy, nephrostomy catheter, urether stent (e.g.
- polyurethane pellets with a size of approximately 1 mm 3 are used as the polymeric material.
- Another component of the preliminary product is barium sulfate, which as
- the barium sulfate contains about 3 to 10% by weight, possibly also deposited more nanosilver.
- the intermediate product comprises about 0.5 to 1% by weight of silver sulfate or silver phosphate, especially in statu nascendi.
- the components of the preliminary product are mixed, the further processing can be done by extrusion.
- a combination of silver and copper in a silver / copper ratio of approximately 2: 1 is used as the metal salt.
- This combination advantageously also has a satisfactory microbial activity against fungi.
- a combination of a metal colloid, particularly preferably nanosilver, and zirconium silicate is used. Weight ratios of silver to zirconium silicate of 1: 1 -10 are particularly suitable.
- Figures 1 to 3 show results of tests for antimicrobial activity. Staphylococcus epidermidis ATCC 14 990 with an initial bacterial count of 5 ⁇ 10 7 CFU / ml was used as the microorganism.
- Figure 3 shows an experimental approach in which 0.8% nanosilver and no additional silver sulfate was used. Examples:
- Comparative Example 1 Commercial plastic according to WO 01/09299 A: Production of a silver colloid
- Example 2 10 minutes after the end of the dropwise addition, as described in Example 1, about 50 g of polyurethane pellets made from Tecothane TT-1085A are added and, for coating with colloidal silver, are stirred vigorously at 40 ° C. for 2 hours and then at room temperature for 3 hours.
- the silver colloid is separated by rapid filtration through a pleated filter with a suitable pore size, the pellets are washed again with the filtrate and the still moist pellets are transferred to an evaporation tray. After removing excess silver colloid solution not adhering to the polymer, drying takes place at 70 ° C. for 10 hours.
- Example 2 Plastic with improved antimicrobial activity.
- A Adsorption of colloidal silver on barium sulfate. In 360 ml of distilled water are successively dissolved at 50 ° C: 0.6 g gelatin and 6.0 g AgNO 3 . 7.8 ml of 25% aqueous ammonia solution are added to the solution. A solution of 3.18 g of anhydrous glucose, dissolved in 120 ml of distilled water, is slowly metered in with vigorous stirring at 50.degree. When about half the amount of glucose has been added dropwise, 100 g of barium sulfate are introduced into the already formed silver colloid with vigorous stirring, and the metering of glucose is continued. After the end of the glucose addition the suspension is turbinated for a further 2 hours at 50 ° C. and then for 3 hours at 70 ° C.
- the solid is then separated from the liquid by filtration or centrifugation.
- the solid is washed several times with ultrapure water until it is free of electrolytes, filtered, dried at 70 ° C to 80 ° C and finely ground.
- step B If 2.5% by weight of silver sulfate is added in step B, the plastic listed in Table 1 under A is obtained; if 5% by weight of silver sulfate is added in step B, the plastic listed in Table 1 under B is obtained.
- Example 3 Plastic with improved antimicrobial activity A: Adsorption of colloidal silver on barium sulfate
- Silver sulfate is added in the same way as in Example 2 B.
- samples of the corresponding plastics were incubated at 37 ° C. with a trypcase soy broth nutrient solution containing various germs.
- Staphylococcus epidermidis ATCC 14 990,
- Staphylococcus aureus ATCC 25923, Escherichia coli (E. coli), fresh clinical isolate from one
- Pseudomonas aeruginosa P. aeruginosa
- fresh clinical isolate from a patient with catheter-associated sepsis.
- the bacterial count was either 5 x 10 7 colony forming units (CFU) / ml (corresponds to an OD of 0.30 at 457 nm for staphylococci, an OD of 0.65 for P. aeruginosa and E. coli) or 10 9 CFU / ml (OD 0.65 for Staphylococci at 475 nm, 1, 2 for P. aeruginosa and E. coli) adjusted in the photometer.
- CFU / ml was determined by serial dilution on agar plates and the bacterial count determined by photometric measurement was confirmed.
- Polyurethane (Tecoflex) was used, a material from which practically all implantable central venous catheters are made. This was with nanosilver (particle size 3 to 5 nm) in an amount of 0.8 or 1, 3 wt .-% and different concentrations of silver sulfate (0.25, 0.5, 0.75 and 1, 0%) coextruded. Strands with an outside diameter of 1.6 mm were produced. Pellets of 1 mm length were cut from each, 10 pellets give a surface area of about 1 cm 2 or 50 pellets give a surface area of 5 cm 2 .
- the plastic pieces (either with a surface area of 1 cm 2 or 5 cm 5 ) were placed in a suspension with either 5 x 10 7 CFU / ml or 10 9 CFU / ml of the germs described above in physiological saline.
- the test tubes were shaken at a speed of 120 rotations / minute.
- 1 eyelet (2 ⁇ ⁇ ) was removed and streaked onto an agar plate (Müller Hinton Agar). The plates were incubated at 37 ° C for 24 hours. The bacterial count on the agar plate was then determined by counting the colonies.
- the wild strain of S. epidermidis, S. aureus ATCC 25923 and E. coli and P. aeruginosa also showed a corresponding growth behavior.
- the test experiments showed that the addition of silver sulfate significantly increases the immediate antimicrobial effectiveness (comparison of A or B against C).
- the increase in effectiveness through the addition of silver sulfate is dose-dependent, however, effectiveness can already be observed with the addition of 0.5% silver sulfate.
- the plastic according to the invention shows a significantly improved antimicrobial effectiveness compared to a plastic which only contains nanosilver (approach C).
- the carrier material barium sulfate is mixed with 20% by weight of zirconium silicate in a first test series and with 20% by weight of nanosilver and 20% by weight of zirconium silicate in a second series of tests.
- the mixtures thus obtained are mixed with different amounts of germs and the germ growth is then recorded over 48 hours.
- the solid obtained is washed several times with ultrapure water until it is free of electrolytes and finally dried in a drying cabinet at 70 to 80 ° C. and, if appropriate, comminuted after drying.
- the product produced in this way is white-gray in color and has the composition 3.6% nanosilver, 5% silver phosphate on BaSO 4 .
- the bacterial count at a concentration of 1% or 0.1% was determined according to Example 4:
- A Adsorption of colloidal silver on barium sulfate. 9 g of silver nitrate are dissolved in 360 ml of distilled water heated to 50 ° C. and 100 g of barium sulfate are stirred vigorously entered. After stirring for 20 minutes, 12 ml of a 25% ammonia solution are added.
- a solution of 5.25 g of glucose monohydrate in 182 ml of distilled water is then slowly metered in at a constant temperature. After the glucose metering has ended, the suspension is stirred for a further 2 to 4 hours at 50 ° C. and then for a further 1 to 3 hours at 70 ° C.
- the solid is separated from the aqueous phase and washed several times with ultrapure water or distilled water until it is free of electrolytes.
- the washed solid is dried in a drying cabinet at 70 to 80 ° C. and then comminuted to the primary grain size.
- Example 7 The desired amount (1 to 5% by weight) of the purest silver phosphate is added to the solid obtained according to A and mixed intensively. The examination as described in Example 4 gave equally good results as shown in Example 7.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coating Of Shaped Articles Made Of Macromolecular Substances (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Heating, Cooling, Or Curing Plastics Or The Like In General (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003270163A AU2003270163A1 (en) | 2002-09-10 | 2003-09-10 | Methods for producing an anti-microbial plastic product |
JP2004535474A JP5128757B2 (ja) | 2002-09-10 | 2003-09-10 | 抗菌性プラスチック製品の製造方法 |
EP03750507A EP1536848B1 (de) | 2002-09-10 | 2003-09-10 | Verfahren zur herstellung eines antimikrobiellen kunststoffproduktes |
DK03750507T DK1536848T3 (da) | 2002-09-10 | 2003-09-10 | Fremgangsmåde til fremstilling af et antimikrobielt plastprodukt |
US10/527,157 US20060134313A1 (en) | 2002-09-10 | 2003-09-10 | Methods for producing an anti-microbial plastic product |
DE50308613T DE50308613D1 (de) | 2002-09-10 | 2003-09-10 | Verfahren zur herstellung eines antimikrobiellen kunststoffproduktes |
BR0314210-8A BR0314210A (pt) | 2002-09-10 | 2003-09-10 | Métodos para a produção de um produto plástico antimicrobiano |
US12/569,423 US20100068296A1 (en) | 2002-09-10 | 2009-09-29 | Methods for producing an anti-microbial plastic product |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10241962.0 | 2002-09-10 | ||
DE10241962 | 2002-09-10 | ||
DE10331324.9 | 2003-07-10 | ||
DE10331324A DE10331324A1 (de) | 2002-09-10 | 2003-07-10 | Verfahren zur Herstellung eines antimikrobiellen Kunststoffproduktes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/569,423 Continuation US20100068296A1 (en) | 2002-09-10 | 2009-09-29 | Methods for producing an anti-microbial plastic product |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004024205A1 true WO2004024205A1 (de) | 2004-03-25 |
Family
ID=31995058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/010049 WO2004024205A1 (de) | 2002-09-10 | 2003-09-10 | Verfahren zur herstellung eines antimikrobiellen kunststoffproduktes |
Country Status (11)
Country | Link |
---|---|
US (2) | US20060134313A1 (de) |
EP (1) | EP1536848B1 (de) |
JP (1) | JP5128757B2 (de) |
CN (1) | CN100342925C (de) |
AT (1) | ATE378078T1 (de) |
AU (1) | AU2003270163A1 (de) |
BR (1) | BR0314210A (de) |
DE (1) | DE50308613D1 (de) |
DK (1) | DK1536848T3 (de) |
ES (1) | ES2297196T3 (de) |
WO (1) | WO2004024205A1 (de) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004052203A1 (de) * | 2004-10-20 | 2006-05-04 | Aesculap Ag & Co. Kg | Trägermaterial mit Silberpartikeln, Bereitstellung des Trägermaterials, medizintechnisches Produkt enthaltend das erfindungsgemäße Material und Verfahren zur Detektion des Trägermaterials sowie von Adhäsionen |
WO2006092155A1 (de) * | 2005-03-02 | 2006-09-08 | Christoph Cichos | Antimikrobiell wirkendes präparat zur äusserlichen anwendung |
EP2018867A1 (de) * | 2007-07-26 | 2009-01-28 | Spirig Pharma AG | Verfahren zur Herstellung einer antimikrobiell wirkender kosmetischen und/oder pharmazeutischen Zusammensetzung zur topischen Anwendung |
WO2009013016A1 (de) * | 2007-07-26 | 2009-01-29 | Spiegelberg (Gmbh & Co.) Kg | Antimikrobielles kunststoffprodukt und verfahren zu dessen herstellung |
EP2108384A1 (de) | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Medizinische Geräte mit einer antibakteriellen Polyurethanharnstoffbeschichtung |
EP2108389A1 (de) | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Medizinische Geräte mit einer antimikrobiellen Polyurethanharnstoffbeschichtung |
EP2108388A1 (de) | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Wässrige silberhaltige nichtionische Polyurethandispersionen |
EP2108382A1 (de) | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Silberhaltige Polyurethanharnstofflösung |
EP2411480A1 (de) * | 2009-03-27 | 2012-02-01 | Panadur GmbH | Antimikrobieller beschichtungsstoff auf der basis eines amino- oder hydroxylgruppenfunktionellen reaktionspartners für isocyanate |
DE102011102635A1 (de) | 2011-05-27 | 2012-11-29 | Spiegelberg GmbH & Co. KG | Verfahren zur Herstellung eines antimikrobiellen Kunststoffproduktes unter Verwendung eines Reduktons |
WO2012163806A1 (de) | 2011-05-27 | 2012-12-06 | Spiegelberg (Gmbh & Co.) Kg | Verfahren zur herstellung eines antimikrobiellen kunststoffproduktes |
DE102005053295C5 (de) * | 2005-11-08 | 2013-03-07 | Spiegelberg GmbH & Co. KG | Verfahren zur Herstellung eines steril verpackten, metallhaltigen Kunststoffkörpers mit antimikrobiell wirkender Oberfläche |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2646639A1 (en) | 2005-03-17 | 2006-09-21 | Impactcare Aps | Article to be inserted in a body cavity having biologically inhibiting surfaces |
US20080086096A1 (en) * | 2006-10-05 | 2008-04-10 | Voznyakovski Alexander Petrovi | Nano particle additives for venous access catheter |
AT12981U1 (de) * | 2006-11-13 | 2013-03-15 | Josef Peter Dr Guggenbichler | Stoff mit antimikrobieller wirkung |
EP2136645B1 (de) * | 2007-04-18 | 2013-06-19 | Basf Se | Antimikrobielle kunststoffe und beschichtungen |
US20100150979A1 (en) * | 2008-12-16 | 2010-06-17 | Cooper Technologies Company | Antimicrobial wiring devices |
IL203403A (en) * | 2010-01-19 | 2016-08-31 | Cupron Inc | Biofilm resistant materials |
DE102010063342A1 (de) | 2010-12-17 | 2012-06-21 | Laser Zentrum Hannover E.V. | Verfahren zur Herstellung von mikro-nanokombinierten Wirksystemen |
KR101944126B1 (ko) * | 2010-12-23 | 2019-04-17 | 프랑코 도크마노비치 해리스 | 항균성 콜로이드 실버 및 골드 제품 및 그의 제조 방법 |
US10138038B2 (en) * | 2014-06-05 | 2018-11-27 | Thomas & Betts International, Llc | Antimicrobial detectable cable tie |
AU2016243634B2 (en) | 2015-03-30 | 2020-04-02 | C. R. Bard, Inc. | Application of antimicrobial agents to medical devices |
CN106178062B (zh) * | 2016-07-08 | 2018-01-23 | 苏州宝迪海斯医疗器械技术开发有限公司 | 一种具有持久抗菌性能的材料及其制备方法 |
WO2020010152A1 (en) | 2018-07-02 | 2020-01-09 | C.R. Bard, Inc. | Antimicrobial catheter assemblies and methods thereof |
MX2021006375A (es) * | 2018-11-29 | 2021-08-11 | Ethicon Inc | Aplicador y metodo para revestimiento de sala de operaciones. |
JP2022550418A (ja) | 2019-10-07 | 2022-12-01 | パーティクル・メージャーリング・システムズ・インコーポレーテッド | 抗菌粒子検出器 |
US11479669B2 (en) | 2020-05-28 | 2022-10-25 | Ethicon, Inc. | Topical skin closure compositions and systems |
US11712229B2 (en) | 2020-05-28 | 2023-08-01 | Ethicon, Inc. | Systems, devices and methods for dispensing and curing silicone based topical skin adhesives |
US11518604B2 (en) | 2020-05-28 | 2022-12-06 | Ethicon, Inc. | Systems, methods and devices for aerosol spraying of silicone based topical skin adhesives for sealing wounds |
US11718753B2 (en) | 2020-05-28 | 2023-08-08 | Ethicon, Inc. | Topical skin closure compositions and systems |
US11589867B2 (en) | 2020-05-28 | 2023-02-28 | Ethicon, Inc. | Anisotropic wound closure systems |
EP4101893A1 (de) * | 2021-06-08 | 2022-12-14 | SHPP Global Technologies B.V. | Thermoplastische zusammensetzungen und daraus geformte artikel |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994004202A1 (de) * | 1992-08-13 | 1994-03-03 | Theodor Krall | Bakterizide und/oder fungizide kunststoffgegenstände für den medizinischen bedarf |
WO1998031404A1 (en) * | 1997-01-22 | 1998-07-23 | St. Jude Medical, Inc. | Medical article with adhered antimicrobial metal ions |
DE19936059A1 (de) * | 1999-07-30 | 2001-02-01 | J Peter Guggenbichler | Verfahren zur Herstellung von antimikrobiellen Kunststoffkörpern |
WO2001024839A1 (en) * | 1999-10-01 | 2001-04-12 | Acrymed | Silver-containing compositions, devices and methods for making |
WO2001043788A2 (en) * | 1999-12-15 | 2001-06-21 | C.R. Bard, Inc. | Polymer compositions containing colloids of silver salts |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US516480A (en) * | 1894-03-13 | Coupling apparatus for air or steam pipes | ||
US4054139A (en) * | 1975-11-20 | 1977-10-18 | Crossley Kent B | Oligodynamic catheter |
US4677143A (en) * | 1984-10-01 | 1987-06-30 | Baxter Travenol Laboratories, Inc. | Antimicrobial compositions |
GB8616294D0 (en) * | 1986-07-03 | 1986-08-13 | Johnson Matthey Plc | Antimicrobial compositions |
US5019096A (en) * | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
US5236649A (en) * | 1988-12-23 | 1993-08-17 | The Dow Chemical | Extrudable thermoplastic particulates |
FI95816C (fi) * | 1989-05-04 | 1996-03-25 | Ad Tech Holdings Ltd | Antimikrobinen esine ja menetelmä sen valmistamiseksi |
US5418056A (en) * | 1989-11-24 | 1995-05-23 | Mitsuboshi Belting Ltd. | Polymer composite with dispersed fine grains and a method for manufacturing the same |
JPH03200702A (ja) * | 1989-12-28 | 1991-09-02 | Toray Ind Inc | 抗菌性樹脂組成物およびその製造方法 |
US5236646A (en) * | 1991-02-28 | 1993-08-17 | The United States Of America As Represented By The Secretary Of The Navy | Process for preparing thermoplastic composites |
US5662913A (en) * | 1991-04-10 | 1997-09-02 | Capelli; Christopher C. | Antimicrobial compositions useful for medical applications |
US5180585A (en) * | 1991-08-09 | 1993-01-19 | E. I. Du Pont De Nemours And Company | Antimicrobial compositions, process for preparing the same and use |
US5503840A (en) * | 1991-08-09 | 1996-04-02 | E. I. Du Pont De Nemours And Company | Antimicrobial compositions, process for preparing the same and use |
GEP20002074B (en) * | 1992-05-19 | 2000-05-10 | Westaim Tech Inc Ca | Modified Material and Method for its Production |
US5681575A (en) * | 1992-05-19 | 1997-10-28 | Westaim Technologies Inc. | Anti-microbial coating for medical devices |
US5312685A (en) * | 1992-07-06 | 1994-05-17 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Atomic oxygen protective coating with resistance to undercutting at defect sites |
US5476881A (en) * | 1993-02-15 | 1995-12-19 | Suh; Kang I. | Antimicrobial composition for manufacturing nipples |
JPH06305906A (ja) * | 1993-04-23 | 1994-11-01 | Nikko:Kk | 抗菌材、抗菌性樹脂組成物、抗菌性合成繊維、抗菌性を有する紙、抗菌性塗料、化粧品および抗菌材の製造方法 |
US5976562A (en) * | 1994-02-01 | 1999-11-02 | Krall; Theodor | Process for producing bactericidal/fungicidal plastic bodies |
DE69521082T2 (de) * | 1994-08-01 | 2002-03-07 | Maruwa Kck Co Ltd | Metallisches bakterizides Mittel |
JP3547259B2 (ja) * | 1996-06-26 | 2004-07-28 | 松下電器産業株式会社 | 抗菌性複合体樹脂組成物並びにその製造方法 |
EP1066825A1 (de) * | 1999-06-17 | 2001-01-10 | The Procter & Gamble Company | Antimikrobielles Körperpflegemittel |
AU6685900A (en) * | 1999-07-30 | 2001-02-19 | J. Peter Guggenbichler | Method of producing antimicrobial synthetic bodies with improved long-term behavior |
-
2003
- 2003-09-10 EP EP03750507A patent/EP1536848B1/de not_active Expired - Lifetime
- 2003-09-10 DE DE50308613T patent/DE50308613D1/de not_active Expired - Lifetime
- 2003-09-10 US US10/527,157 patent/US20060134313A1/en not_active Abandoned
- 2003-09-10 ES ES03750507T patent/ES2297196T3/es not_active Expired - Lifetime
- 2003-09-10 AU AU2003270163A patent/AU2003270163A1/en not_active Abandoned
- 2003-09-10 JP JP2004535474A patent/JP5128757B2/ja not_active Expired - Fee Related
- 2003-09-10 DK DK03750507T patent/DK1536848T3/da active
- 2003-09-10 BR BR0314210-8A patent/BR0314210A/pt not_active Application Discontinuation
- 2003-09-10 CN CNB038233320A patent/CN100342925C/zh not_active Expired - Fee Related
- 2003-09-10 AT AT03750507T patent/ATE378078T1/de active
- 2003-09-10 WO PCT/EP2003/010049 patent/WO2004024205A1/de active IP Right Grant
-
2009
- 2009-09-29 US US12/569,423 patent/US20100068296A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994004202A1 (de) * | 1992-08-13 | 1994-03-03 | Theodor Krall | Bakterizide und/oder fungizide kunststoffgegenstände für den medizinischen bedarf |
WO1998031404A1 (en) * | 1997-01-22 | 1998-07-23 | St. Jude Medical, Inc. | Medical article with adhered antimicrobial metal ions |
DE19936059A1 (de) * | 1999-07-30 | 2001-02-01 | J Peter Guggenbichler | Verfahren zur Herstellung von antimikrobiellen Kunststoffkörpern |
WO2001024839A1 (en) * | 1999-10-01 | 2001-04-12 | Acrymed | Silver-containing compositions, devices and methods for making |
WO2001043788A2 (en) * | 1999-12-15 | 2001-06-21 | C.R. Bard, Inc. | Polymer compositions containing colloids of silver salts |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004052203A1 (de) * | 2004-10-20 | 2006-05-04 | Aesculap Ag & Co. Kg | Trägermaterial mit Silberpartikeln, Bereitstellung des Trägermaterials, medizintechnisches Produkt enthaltend das erfindungsgemäße Material und Verfahren zur Detektion des Trägermaterials sowie von Adhäsionen |
WO2006092155A1 (de) * | 2005-03-02 | 2006-09-08 | Christoph Cichos | Antimikrobiell wirkendes präparat zur äusserlichen anwendung |
DE102005053295C5 (de) * | 2005-11-08 | 2013-03-07 | Spiegelberg GmbH & Co. KG | Verfahren zur Herstellung eines steril verpackten, metallhaltigen Kunststoffkörpers mit antimikrobiell wirkender Oberfläche |
EP2018867A1 (de) * | 2007-07-26 | 2009-01-28 | Spirig Pharma AG | Verfahren zur Herstellung einer antimikrobiell wirkender kosmetischen und/oder pharmazeutischen Zusammensetzung zur topischen Anwendung |
WO2009013343A1 (de) * | 2007-07-26 | 2009-01-29 | Spirig Pharma Ag | Antimikrobiell wirkende kosmetische und/oder pharmazeutische zusammensetzungen zur topischen anwendung, verfahren zu deren herstellung und ihre anwendung in der behandlung von krankheiten |
WO2009013016A1 (de) * | 2007-07-26 | 2009-01-29 | Spiegelberg (Gmbh & Co.) Kg | Antimikrobielles kunststoffprodukt und verfahren zu dessen herstellung |
DE102007035063A1 (de) | 2007-07-26 | 2009-01-29 | Spiegelberg (Gmbh & Co.) Kg | Verfahren zur Herstellung eines antimikrobiellen Kunststoffproduktes |
US8673441B2 (en) | 2007-07-26 | 2014-03-18 | Spiegelberg (Gmbh & Co.) Kg | Antimicrobial plastics product and process for production thereof |
EP2108386A1 (de) | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Medizinische Geräte mit einer antimikrobiellen Polyurethanharnstoffbeschichtung |
EP2108383A1 (de) | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Medizinische Geräte mit einer antibakteriellen Polyurethanharnstoffbeschichtung |
EP2108388A1 (de) | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Wässrige silberhaltige nichtionische Polyurethandispersionen |
EP2108382A1 (de) | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Silberhaltige Polyurethanharnstofflösung |
EP2108385A1 (de) | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Silberhaltige Polyurethanharnstofflösung |
EP2108387A1 (de) | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Wässrige silberhaltige nichtionische Polyurethandispersionen |
EP2108389A1 (de) | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Medizinische Geräte mit einer antimikrobiellen Polyurethanharnstoffbeschichtung |
EP2108384A1 (de) | 2008-04-08 | 2009-10-14 | Bayer MaterialScience AG | Medizinische Geräte mit einer antibakteriellen Polyurethanharnstoffbeschichtung |
EP2411480A1 (de) * | 2009-03-27 | 2012-02-01 | Panadur GmbH | Antimikrobieller beschichtungsstoff auf der basis eines amino- oder hydroxylgruppenfunktionellen reaktionspartners für isocyanate |
DE102011102635A1 (de) | 2011-05-27 | 2012-11-29 | Spiegelberg GmbH & Co. KG | Verfahren zur Herstellung eines antimikrobiellen Kunststoffproduktes unter Verwendung eines Reduktons |
WO2012163806A1 (de) | 2011-05-27 | 2012-12-06 | Spiegelberg (Gmbh & Co.) Kg | Verfahren zur herstellung eines antimikrobiellen kunststoffproduktes |
WO2012163809A1 (de) | 2011-05-27 | 2012-12-06 | Spiegelberg (Gmbh & Co.) Kg | Verfahren zur herstellung eines antimikrobiellen kunststoffproduktes unter verwendung eines reduktons |
Also Published As
Publication number | Publication date |
---|---|
ES2297196T3 (es) | 2008-05-01 |
CN100342925C (zh) | 2007-10-17 |
US20100068296A1 (en) | 2010-03-18 |
CN1684724A (zh) | 2005-10-19 |
BR0314210A (pt) | 2005-06-28 |
DK1536848T3 (da) | 2008-03-17 |
EP1536848A1 (de) | 2005-06-08 |
US20060134313A1 (en) | 2006-06-22 |
AU2003270163A1 (en) | 2004-04-30 |
DE50308613D1 (de) | 2007-12-27 |
JP2006509054A (ja) | 2006-03-16 |
EP1536848B1 (de) | 2007-11-14 |
ATE378078T1 (de) | 2007-11-15 |
JP5128757B2 (ja) | 2013-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1536848B1 (de) | Verfahren zur herstellung eines antimikrobiellen kunststoffproduktes | |
EP0655002B1 (de) | Bakterizide und/oder fungizide kunststoffgegenstände für den medizinischen bedarf | |
DE3725728C2 (de) | ||
EP2091333B1 (de) | Stoff mit antimikrobieller wirkung | |
EP1790224B1 (de) | Antimikrobielles Schichtmaterial | |
EP2176329B1 (de) | Antimikrobielles kunststoffprodukt und verfahren zu dessen herstellung | |
DE19936059A1 (de) | Verfahren zur Herstellung von antimikrobiellen Kunststoffkörpern | |
EP1210386B1 (de) | Verfahren zur herstellung von antimikrobiellen kunststoffkörpern mit verbessertem langzeitverhalten | |
EP0433961A2 (de) | Medizinische Vorrichtung mit einem oligodynamisch wirkenden Material | |
EP2217296B1 (de) | Chirugisches Nahtmaterial | |
EP2498833B1 (de) | Verwendung polymerer oder oligomerer wirkstoffe für medizinische artikel | |
EP2498834B1 (de) | Verwendung von polyoxyalkylendiamin-basierten polyguanidinderivaten für medizinische artikel | |
EP2185208B1 (de) | Brust-implantat mit antibakterieller wirkung | |
DE10331324A1 (de) | Verfahren zur Herstellung eines antimikrobiellen Kunststoffproduktes | |
WO2014138885A1 (en) | Polymeric coatings having antimicrobial properties | |
DE10013248A1 (de) | Verfahren zur Herstellung von antimikrobiellen Kunststoffkörpern mit verbessertem Langzeitverhalten | |
WO2004063099A1 (de) | Kaltkeramik |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006134313 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10527157 Country of ref document: US Ref document number: 345/CHENP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004535474 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038233320 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003750507 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003750507 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10527157 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003750507 Country of ref document: EP |